Thoracoscopic staging and surgical therapy for esophageal cancer.
Esophageal cancer continues to be a major health problem with an associated poor prognosis. New technology is being applied to the staging of this cancer. The new staging system requires assessment of depth of wall penetration and lymph node status prior to resection. To determine penetration and node status with a high degree of accuracy generally requires some combination of chemotherapy, magnetic resonance imaging, endoesophageal ultrasound, and/or surgical staging. Several variables need to be considered in planning the surgical approach to the patient with esophageal cancer: the intent of the surgeon to either cure or palliate, the anatomic location of the tumor, and the method of reconstruction. Surgery is optimal for localized esophageal cancer. Neoadjuvant chemoradiation has increased survival in specific subgroups. Phase 2 trials have shown the safety and efficacy of chemoradiation. Randomized multi-institutional trials are needed to verify the encouraging results of recent phase 2 trials.
Sugarbaker
D J
DJ
Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Jaklitsch
M T
MT
Liptay
M J
MJ
D017024:Chemotherapy, Adjuvant; D004938:Esophageal Neoplasms / Q000473:pathology* / Q000601:surgery*; D006801:Humans; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D013906:Thoracoscopy; D016896:Treatment Outcome